

AT A GLANCE

04/02/2024

Coronavirus Disease 2019 (COVID-19), Influenza, & Respiratory Syncytial Virus (RSV)

Updated weekly on Tuesdays, and current as of 3:00 p.m. on the date it was posted.

Note: As of October 17, 2023 this document will include updates for other respiratory diseases of public health concern, primarily influenza and respiratory syncytial virus (RSV).

Additionally, the "Guidelines and Technical documents" section [last updated July 26, 2023] will no longer be updated, but is archived as an appendix at the end of this document.

Moving forward, any news and guidance updates will be cycled through the <u>New Content</u> section below, as always with the dates of the latest additions **bolded.**

This document is a collation of resources for your reference. For official guidance on COVID-19, Influenza, and RSV in Ontario, please visit the Ministry of Health (COVID-19 | The Flu | RSV).

Table of Contents

New Content	3
Public Health Agencies	3
Public Health Agency of Canada canada.ca	3
BC Centre for Disease Control bccdc.ca	3
Institut national de santé publique inspq.qc.ca inspq.qc.ca/en/	3
CDC: Centers for Disease Control and Prevention cdc.gov	3
ECDC: European Centre for Disease Prevention and Control ecdc.europa.eu	4
FDA: U.S. Food & Drug Administration fda.gov	4
UK Government gov.uk	5
World Health Organization who.int	5
Other relevant government bodies / health care organizations	6
Center for Infectious Disease Research Policy cidrap.umn.edu	6
National Collaborating Centre for Environmental Health ncceh.ca	7



COVID-END www.mcmasterforum.org/networks/covid-end	7
ProMED promedmail.org	7
Data & Real-time Tracking	7
COVID-19 resources (case counts) arcgis.com	7
COVID-19 Canada Open Data Working Group COVID-19 CODWG	7
Johns Hopkins CCSE systems.jhu.edu	7
NextStrain nextstrain.org	7
WHO who.int	7
Appendices	8
Guidelines and Technical documents [ARCHIVED]	8
Appendix I: General Guidelines [ARCHIVED]	8
Ontario / Canada Main Page	8
Reopening/Rebuilding Guidelines	8
Vaccinations – General	9
Vaccinations - Adverse Effects	10
Background Information/Case Definitions	10
Laboratories	11
Miscellaneous Guidelines	11
Data & Surveillance	11
Variants – Omicron	12
Testing	12
Symptoms/Treatment	12
COVID-19 Diagnosis in Children	13
Post-COVID-19 Condition	13
Case Investigation & Contact Tracing	14
Infection Prevention and Control	14
Appendix II: Guidelines for Health Sectors [ARCHIVED]	14
Healthcare Providers	14
Congregate Living (including Long-Term Care, Prisons, and Shelters)	15
Appendix III: Guidelines for the Community [ARCHIVED]	15
Travel, Transport & Borders	15
Schools / Childcare	16
Mental Health/Substance Use Health	16
Community/Workplaces	17

New Content

Public Health Agencies

Public Health Agency of Canada | canada.ca

- COVID-19 epidemiology update: testing and variants [updated 03-26-2024]
 - Change to scheduled update -- this page will be updated on Wednesday, April 3, 2024, instead of Tuesday. Regular Tuesday updates will resume the following week.
- Key COVID updates [updated 03-26-2024]
 - Weekly change in cases: 2,296
 - o Total cases: 4,944,196
 - Weekly change in deaths: 35
 - o Total deaths: 58,972
 - Weekly tests reported: 32,252
 - Weekly percent positivity: 6.1%
- COVID-19 activity levels [updated 03-26-2024]
- FluWatch summary: March 10 to March 16, 2024 (week 11) [03-22-2024]
- COVID-19 daily epidemiology update [updated regularly]
- Respiratory virus detections in Canada [updated regularly]

BC Centre for Disease Control | bccdc.ca

- Epi week 12: Mar 17 to Mar 23, 2024 [03-28-2024]
- COVID-19 situation report [updated 03-28-2024]
- Genomic surveillance [updated 03-21-2024]
- Wastewater surveillance [updated 03-21-2024]
- Acute care and long-term care outbreaks [updated 03-21-2024]
- Emergency department visits for respiratory illness in BC [updated 03-21-2024]
- <u>Viral pathogen characterization</u> [updated 03-21-2024]
- Primary care visits for respiratory illness [updated 03-21-2024]
- Respiratory season reports [updated regularly]

Institut national de santé publique | inspq.qc.ca | inspq.qc.ca/en/

- Perceptions, attitudes et comportements 9 mars 2024 [03-27-2024]
- Vaccination contre la COVID-19 : recommandations pour le printemps 2024 [03-20-2024]
- Surveillance de l'influenza et des infections respiratoires virales [03-04-2024]

CDC: Centers for Disease Control and Prevention | cdc.gov

- Highly pathogenic avian influenza A (H5N1) virus infection reported in a person in the U.S. [04-01-2024]
 - o CDC's risk assessment for the general public remains low
- <u>United States COVID-19 hospitalizations, deaths, emergency department (ED) visits, and test positivity by geographic area</u> [updated 04-01-2024]
- Weekly U.S. influenza surveillance report [03-29-2024]
- Respiratory Virus Data Channel weekly snapshot [updated 03-29-2024]

- <u>Severe viral respiratory illness</u> [updated 03-29-2024]
- Respiratory virus activity levels [updated 03-29-2024]
- Groups most impacted—emergency department visits [updated 03-29-2024]
- Vaccination trends—children [updated 03-29-2024]
- MMWR. Interim effectiveness of updated 2023–2024 (monovalent XBB.1.5) COVID-19 vaccines against COVID-19—associated hospitalization among adults aged ≥18 years with immunocompromising conditions VISION Network, September 2023–February 2024 [03-28-2024]
- Immunization and Respiratory Diseases Bulletin [updated regularly]
- <u>COVID Data Tracker</u> [updated regularly]
- Respiratory virus index [updated regularly]

ECDC: European Centre for Disease Prevention and Control | ecdc.europa.eu

- Communicable disease threats report, 24-30 March 2024, week 13 [03-27-2024]
- Avian influenza overview December 2023–March 2024 [03-26-2024]
- Overview of respiratory virus epidemiology in the EU/EEA weekly overview (week 11, 2024) [03-19-2024]

ECDC and the WHO Regional Office for Europe have jointly developed the European Respiratory Virus Surveillance Summary (ERVISS)

- Syndromic surveillance in primary and secondary care indicate that respiratory activity is decreasing but remains above baseline levels in under half of reporting EU/EEA countries. The activity is largely driven by influenza.
 - All indicators pointed to elevated but decreasing influenza activity in the EU/EEA.
 - At the EU/EEA level, a decreasing trend in pooled sentinel primary care
 positivity for influenza has been observed since week 4, 2024, although the
 majority of reporting countries remained above the 10% positivity threshold for
 influenza.
 - The majority of countries now report medium or low levels of influenza intensity, widespread but decreasing geographical spread, and baseline rates of influenza-like illness (ILI). Stable or decreasing trends in indicators of activity and severe disease were also observed in most reporting countries.
 - A(H1)pdm09 continues to be the most commonly detected virus in the EU/EEA.
 Influenza B is now dominant in five countries although the number of influenza
 B detections remain low overall.
 - Interim influenza vaccine effectiveness estimates for the 2023–2024 season indicate that up to 53% and 44% of vaccinated individuals in primary care or hospital settings, respectively, were protected against mild and severe influenza.
- RSV activity continued to decrease to low levels at the EU/EEA level and in most reporting countries.
- SARS-CoV-2 activity remained low in all EU/EEA countries.
- Public health and social measures for health emergencies and pandemics in the EU/EEA: recommendations for strengthening preparedness planning [03-20-2024]

FDA: U.S. Food & Drug Administration | <u>fda.gov</u>

• FDA roundup: March 22, 2024 [03-22-2024]

- <u>Fact sheet for healthcare providers: Emergency Use Authorization of Pemgarda (pemivibart)</u> [03-22-2024]
 - "The U.S. FDA has issued an EUA for the emergency use of the unapproved product PEMGARDA (pemivibart), a SARS-CoV-2 spike protein-directed attachment inhibitor, for the pre-exposure prophylaxis of coronavirus disease 2019 (COVID-19) in adults and adolescents (12 years of age and older weighing at least 40 kg)"
- Frequently asked questions on the emergency use authorization of Pemgarda [03-22-2024]
- Fact sheet for patients, parents, and caregivers Emergency Use Authorization (EUA) of Pemgarda (pemivibart) for coronavirus disease 2019 (COVID-19) [03-22-2024]
- Vaccines and Related Biological Products Advisory Committee May 16, 2024 meeting announcement [02-26-2024]
- Coronavirus (COVID-19) update: daily roundup [updated regularly]

UK Government | gov.uk

- UK Health Security Agency
 - National protocol for COVID-19 mRNA vaccine (5 to 17 years of age) [updated 04-02-2024]
 - o National protocol for COVID-19 vaccine (adults) [updated 04-02-2024]
 - Winter Coronavirus (COVID-19) Infection Study, England and Scotland: 28 March 2024
 [03-28-2024]
 - o COVID-19 PCR home test kit instructions [updated 03-28-2024]
 - o How to do a coronavirus (COVID-19) rapid lateral flow test [updated 03-28-2024]
 - Infection prevention and control in adult social care: acute respiratory infection
 [updated 03-28-2024]
 - o <u>Latest measles statistics published</u> [updated 03-28-2024]
 - Measles epidemiology 2023 and 2024 [updated 03-28-2024]
 - National flu and COVID-19 surveillance reports: 2023 to 2024 season [updated 03-28-2024]
 - SARS-CoV-2: genome sequence prevalence and growth rate [updated 03-27-2024]
 - Seasonal influenza vaccine uptake in GP patients: monthly data, 2023 to 2024 [updated 03-28-2024]
- UK Medicines and Healthcare products Regulatory Agency
 - o Regulatory approval of Pfizer/BioNTech vaccine for COVID-19 [updated 03-21-2024]

World Health Organization | who.int

- The burden of Influenza [03-30-2024]
- <u>Influenza health worker vaccination programmes: platforms for pandemic preparedness</u> [03-30-2024]
- <u>Updated public health resource pack for countries experiencing outbreaks of influenza in</u> animals published **[03-30-2024]**
- 2023: outbreaks of swine influenza **[03-30-2024]**
- <u>2023: outbreaks of avian influenza</u> **[03-30-2024]**
- Indoor airborne risk assessment in the context of SARS-CoV-2: description of airborne transmission mechanism and method to develop a new standardized model for risk assessment [03-27-2024]
- WHO launches CoViNet: a global network for coronaviruses [03-27-2024]

- WHO Director-General's video message at WHO Civil Society Commission first annual general meeting 26 March 2024 [03-26-2024]
 - "One of the most important lessons of the COVID-19 pandemic is that civil society organizations play a vital role in supporting the communities they represent to protect and promote their own health, based on reliable information. That's especially true of the pandemic agreement that WHO's Member States are negotiating as we speak. As you know, just as the response to the COVID-19 pandemic was hampered by mis- and disinformation, so are the negotiations on the pandemic agreement. I'm sure you are aware of some of the lies being spread about the agreement: that it's a power grab by WHO that will cede national sovereignty to WHO and give it the power to impose lockdowns or vaccine mandates on countries. These claims are completely false. In fact, the draft agreement says explicitly – in Article 24, paragraph 3 – that the pandemic agreement will not give WHO any power to dictate or change the laws or policies of any country, nor to impose vaccine mandates or lockdowns. We cannot allow this historic agreement to be sabotaged by those who spread lies, either knowingly or unknowingly. We need your help, both to advocate for the agreement, and to counter the mis- and disinformation against it - especially in the communities you represent. If that happens, we may lose the opportunity to put in place an agreement to protect future generations from the impact of pandemics."
- Recommended composition of influenza virus vaccines for use in the 2024–2025 northern hemisphere influenza season [03-22-2024]
- WHO COVID-19 dashboard [updated regularly]

Other relevant government bodies / health care organizations

- Canadian Centre for Occupational Health and Safety
 - COVID-19 health and safety resources [updated regularly]
- Statistics Canada
 - Nursing and residential care facilities, 2022 [03-19-2024]
 - o Canadian health and COVID-19 survey [03-15-2024]

Center for Infectious Disease Research Policy | cidrap.umn.edu

- Study describes more severe pediatric mental health crises during pandemic [04-02-2024]
- Tests confirm avian flu on New Mexico dairy farm, probe finds cat positives [04-02-2024]
- Quick takes: US measles total climbs to 97, Novavax COVID vaccine data [04-01-2024]
- Avian flu infects person exposed to sick cows in Texas
- US flu, COVID-19, RSV levels all decline [03-29-2024]
- States that lean Republican report more COVID vaccine-related adverse events, study finds [03-29-2024]
- Pennsylvania reports H1N2v flu case [03-29-2024]
- Avian flu detected in Idaho dairy cows [03-29-2024]
- Study: COVID booster cuts severe COVID risk by a third in patients with weak immune systems [03-28-2024]
- Asking patients about flu shots in the emergency room may boost uptake [03-28-2024]
- Avian flu detections in dairy cows raise more key questions [03-27-2024]
- Study: Kids with COVID but no symptoms play key role in household spread [03-26-2024]
- Sick cows in 2 states test positive for avian flu [03-25-2024]

National Collaborating Centre for Environmental Health | ncceh.ca

- January 2024 environmental health research scan [01-01-2024]
- December 2024 environmental health research scan [12-01-2023]

COVID-END | www.mcmasterforum.org/networks/covid-end

• Global spotlight 27.1: key additions for March 2023 [03-30-2023]

ProMED | promedmail.org

- <u>Latest on COVID-19</u> [individual posts]
- Avian influenza, human USA (01): (TX) H5N1 ex dairy cows, RFI [04-01-2024]
- Measles South Sudan: (WE) increasing incidence, fatal [03-31-2024]
- Measles USA (30): (IL) Chicago, more cases [03-30-2024]
- Influenza (04): USA (PA) H1N2v, swine origin [03-30-2024]
- Measles USA (29): (IL) Chicago, more cases [03-28-2024]
- Measles Yemen [03-27-2024]
- Measles Netherlands (02): more cases [03-26-2024]
- Measles USA (28): (IL) Chicago, more cases, vaccine response [03-26-2024]
- Measles USA (27): (IL) Chicago, more cases [03-25-2024]
- Avian influenza, human Viet Nam (03): (KH) H5N1, additional information [03-24-2024]
- Avian influenza, human Viet Nam (02): (KH) H5N1, fatal [03-24-2024]
- Measles USA (26): (IL) more cases in and around Chicago [03-24-2024]
- COVID-19 update (16): selected locations, vaccine effectiveness, WHO update [03-24-2024]

Back to Top

Data & Real-time Tracking

COVID-19 resources (case counts) | arcgis.com

• Canada COVID-19 Note: has ceased updates as of 07-03-2023

COVID-19 Canada Open Data Working Group | COVID-19 CODWG

COVID-19 in Canada (case count dashboard)

Johns Hopkins CCSE | systems.jhu.edu

• 2019-nCoV Global Cases (by Johns Hopkins CSSE)

NextStrain | nextstrain.org

- Phylogeny of SARS-like betacoronaviruses including novel coronavirus (nCoV)
- Genomic epidemiology of novel coronavirus (nCoV)
- Genomic analysis of nCoV spread. Situation report 2020-01-30

WHO | who.int

WHO coronavirus (COVID-2019) dashboard

Appendices

Guidelines and Technical documents [ARCHIVED]

The guidelines were last updated **07-26-2023**; news and updated guidance can be found in the <u>New Content</u> section above.

Appendix I: General Guidelines [ARCHIVED]

Ontario / Canada Main Page

- Ontario guidance
- Canadian guidance (federal)

Reopening/Rebuilding Guidelines

Ontario

ON Protection from COVID-19 and other respiratory illnesses [updated 06-15-2023]

Canada (federal) and provinces and territories (other than Ontario)

- CA Guidance for a strategic approach to lifting restrictive public health measures [06-10-2022]
- CA <u>COVID-19</u>: readiness criteria and indicators for easing restrictive public health measures [05-14-2021]
- BC B.C.'s response to COVID-19 [updated 02-11-2023]
- AB COVID-19 public health actions [no date]
- SK Living with COVID [no date]
- MB COVID-19 Novel Coronavirus [no date]
- QC Coronavirus disease (COVID-19) in Québec [updated 07-20-2023]
- NB <u>Living with COVID-19</u> [no date]
- NL NL life with COVID-19 [no date]
- PEI COVID-19 [no date]
- NS <u>Government's response to COVID-19</u> [updated regularly]
- NW COVID-19 [no date]
- YT Forging ahead: the Yukon's continuing response to COVID-19 [no date]
- NT Nunavut's Path: living with COVID-19 [no date]
- National Collaborating Centre for Indigenous Health (NCCIH): Guidance on re-opening northern, remote, isolated, and Indigenous communities [2020]

WHO

• End-to-end integration of SARS-CoV-2 and influenza sentinel surveillance: compendium of country approaches [08-02-2023]

• Considerations for implementing and adjusting public health and social measures in the context of COVID-19: interim guidance [03-30-2023]

ECDC

• Conducting after-action reviews of the public health response to COVID-19: update [03-21-2023]

Back to Top

Vaccinations – General

Ontario Ministry of Health

COVID-19 vaccine-relevant information and planning resources [updated 07-13-2023]

Canada (Federal)

- Planning guidance for immunization clinics for COVID-19 vaccines [updated 03-06-2023]
- For immunization providers: Interim national vaccine storage, handling and transportation guidelines for ultra-low temperature and frozen temperature COVID-19 vaccines [updated 07-31-2023]
- Guidance on the use of COVID-19 vaccines in the fall of 2023 [updated 07-11-2023]
- <u>Interim guidance on the use of bivalent Omicron-containing COVID-19 vaccines for primary series</u> [updated 07-05-2023]
- Summary of updates in the Canadian Immunization Guide as of June 27, 2023: Updated guidance on COVID-19 vaccines in Canada [updated 06-27-2023]

Provinces and territories (other than Ontario)

BC <u>COVID-19 vaccine eligibility</u> [updated 08-01-2023]

CDC

- Stay up to date with COVID-19 vaccines including boosters [updated 07-17-2023]
- COVID-19 vaccines for specific groups of people [updated 06-29-2023]

UK

- <u>COVID-19 vaccination programme</u> [updated 08-08-2023]
- COVID-19 vaccination: vaccine product information [07-18-2023]
- COVID-19: the green book, chapter 14a [04-27-2023]

ECDC

- Interim public health considerations for COVID-19 vaccination roll-out during 2023 [04-05-2023]
- Interim analysis of COVID-19 vaccine effectiveness against severe acute respiratory infection due to laboratory-confirmed SARS-CoV-2 among individuals aged 30 years and older, ECDC multi-country study – third update [modified 03-16-2023]
- Overview of the implementation of COVID-19 vaccination strategies and vaccine deployment plans in the EU/EEA [updated 03-03-2023]

Australia

- COVID-19 booster vaccine advice [updated 04-05-2023]
- Clinical recommendations for COVID-19 vaccines [updated 03-21-2023]
- ATAGI clinical guidance for COVID-19 vaccine providers [updated 02-17-2023]

Back to Top

Vaccinations - Adverse Effects

Canada (Federal)

• Reporting ocular adverse events following COVID-19 vaccination: Communiqué to healthcare professionals (May 30, 2022) [05-30-2022]

Provinces and territories (other than Ontario)

• BC <u>Guidance document on the management of inadvertent vaccine errors</u> [11-04-2022]

CDC

Reported adverse events [updated 07-13-2023]

WHO

• Guidance for clinical case management of thrombosis with thrombocytopenia syndrome (TTS) following vaccination to prevent coronavirus disease (COVID-19) [03-31-2023]

UK

- Coronavirus (COVID-19) vaccines adverse reactions [updated 03-08-2023]
- Myocarditis and pericarditis after COVID-19 vaccination [updated 01-09-2023]

Australia

- ATAGI clinical guidance on COVID-19 vaccine administration errors [updated 06-05-2023]
- COVID-19 vaccination guidance on myocarditis and pericarditis after mRNA COVID-19 vaccines
 [11-09-2022]

Back to Top

Background Information/Case Definitions

Ontario Ministry of Health

Ontario case definition - coronavirus disease (COVID-19) [updated 05-00-2023]

PHAC

National case definition: coronavirus disease (COVID-19) [updated 06-06-2023]

CDC

Coronavirus disease 2019 (COVID-19) 2023 case definition [reviewed 02-28-2023]

WHO

- WHO COVID-19 Case definition [updated 07-22-2022]
- A clinical case definition of post COVID-19 condition by a Delphi consensus, 6 October 2021 [10-06-2021]

ECDC

• Reinfection with SARS-CoV-2: implementation of a surveillance case definition within the EU/EEA [04-08-2021]

UK

COVID-19: epidemiology, virology and clinical features [05-17-2022]

Australia

• COVID-19 disease, symptoms and variants [updated 12-09-2022]

Other

• BMJ best practice COVID-19 [updated regularly]

Back to Top

Laboratories

Ontario Ministry of Health

Management of cases and contacts of COVID-19 in Ontario (version 15.2) [06-09-2023]

PHAC

• Requirements for serological antibody tests submitted under the COVID-19 interim order: guidance [modified 02-22-2023]

CDC

• Interim guidelines for COVID-19 antibody testing: interim guidelines for COVID-19 antibody testing in clinical and public health settings [updated 12-16-2022]

Back to Top

Miscellaneous Guidelines

PHAC

- COVID-19 and people with disabilities in Canada [updated 01-30-2023]
- <u>Individual public health measures</u> [updated 01-27-2023]
- Summary of evidence supporting COVID-19 public health measures [updated 01-27-2023]

CDC

• <u>CDC Archive</u>: Archived web material for CDC.gov is preserved on the CDC Archive Site. Note that the content on this site is for historical purposes only and is no longer being updated. The information here may be outdated and links may no longer function.

WHO

 Considerations in adjusting public health and social measures in the context of COVID-19: interim guidance [updated 03-30-2023]

Back to Top

Data & Surveillance

Canada

- COVID-19 data trends [modified 03-06-2023]
- National surveillance guidelines for coronavirus disease (COVID-19) [03-19-2021]

WHO

• Public health surveillance for COVID-19: interim guidance [07-22-2022]

CDC

• <u>COVID-19 serology surveillance</u> [03-11-2021]

ECDC

- Organisation of vector surveillance and control in Europe [12-13-2021]
- Surveillance of COVID-19 in long-term care facilities in the EU/EEA [11-29-2021]

Back to Top

Variants – Omicron

Canada

• SARS-CoV-2 variants: national definitions, classifications and public health actions [08-18-2022]

CDC

• What is genomic surveillance? [updated 12-02-2022]

UK

- <u>Investigation of SARS-CoV-2 variants</u> [updated 03-10-2023]
- SARS-CoV-2 variants of public health interest [updated 03-10-2023]

ECDC

 Methods for the detection and characterisation of SARS-CoV-2 variants – second update [08-02-2022]

Testing

Canada

• Interim guidance on the use of rapid antigen detection tests for the identification of SARS-CoV-2 infection [07-07-2022]

Ontario Ministry of Health

- Management of cases and contacts of COVID-19 in Ontario Version 15.2 [03-27-2023]
- COVID-19 provincial testing guidance. Version 15.3 [01-25-2023]

Canadian provinces and territorities (other than Ontario)

• BC COVID-19: viral testing guidelines for British Columbia [09-28-2022]

WHO

 Use of SARS-CoV-2 antigen-detection rapid diagnostic tests for COVID-19 self-testing [03-09-2022]

CDC

- Guidance for healthcare workers about COVID-19 (SARS-CoV-2) testing [updated 12-20-2022]
- <u>Using antibody tests for COVID-19</u> [updated 12-16-2022]

UK

- Investigation of SARS-CoV-2 variants: technical briefings [updated 02-10-2023]
- SARS-CoV-2 variants of public health interest [updated 02-10-2023]

ECDC

Methods for the detection and identification of SARS-CoV-2 variants- first update [08-02-2022]

Back to Top

Symptoms/Treatment

Canada

COVID-19 signs, symptoms and severity of disease: a clinician guide [06-01-2022]

Ontario Ministry of Health

Management of cases and and contacts of COVID-19 in Ontario version 15.2 [updated 03-27-2023]

BC

 Clinical practice guide for the use of therapeutics in mild-moderate COVID-19 [updated 01-10-2023]

WHO

- WHO living guideline: drugs to prevent COVID-19 [updated 03-24-2023]
- <u>Clinical care of severe acute respiratory infections tool kit: COVID-19 adaptation, update 2022</u> [04-06-2022]
- Living guidance for clinical management of COVID-19 [11-23-2021]

CDC

- Underlying medical conditions associated with higher risk for severe COVID-19: information for healthcare providers [updated 02-09-2023]
- <u>Clinical care information for COVID-19</u> [updated 01-30-2023]
- Clinical considerations for care of children and adults with confirmed COVID-19 [updated 01-27-2023]
- <u>Post-COVID Conditions: Information for Healthcare Providers</u> [updated 12-16-2022]
- <u>Clinical considerations for care of children and adults with confirmed COVID-19</u> [updated 01-27-2023]
- Care for breastfeeding people: interim guidance on breastfeeding and breast milk feeds in the context of covid-19 [02-25-2022]

US NIH

<u>COVID-19 treatment guidelines</u> [updated 03-06-2023]

UK

• Find help and support if you have long COVID [updated 03-29-2023]

Back to Top

COVID-19 Diagnosis in Children

Canada

COVID-19 signs, symptoms and severity of disease: COVID-19 symptoms in children [06-22-2022]

WHO

 A clinical case definition for post COVID-19 condition in children and adolescents by expert consensus [02-16-2023]

CDC

Information for Pediatric Healthcare Providers [02-10-2023]

Other

• American Academcy of Pediatrics What is the case definition of multisystem inflammatory syndrome in children (MIS-C) interim guidance [02-08-2023]

Post-COVID-19 Condition

Canada

Post COVID-19 condition (long COVID) [modified 03-09-2023]

Ontario

Ontario Health Post COVID-19 condition: guidance for primary care [12-00-2022]

WHO

• Post COVID-19 condition [12-16-2021]

CDC

Post-COVID conditions; CDC Science [updated 03-31-2023]

UK

• Long-term effects of coronavirus (long COVID) [reviewed 03-21-2023]

Case Investigation & Contact Tracing

Canada

Public health management of cases and contacts associated with COVID-19 [01-30-2023]

Ontario

Management of cases and contacts of COVID-19 in Ontario (version 15.2) [03-27-2022]

CDC

<u>Isolation and precautions for people with COVID-19</u> [03-21-2023]

UK

• COVID-19 rapid guideline: managing COVID-19 NICE guideline [NG191] [03-29-2023]

Back to Top

Infection Prevention and Control

PHAC / Health Canada

- At home: using ventilation and filtration to reduce the risk of aerosol transmission of COVID-19
 [01-27-2023]
- Coronavirus disease (COVID-19): prevention and risks [01-27-2023]
- COVID-19 mask use: advice for community settings [01-30-2023]

Ontario

• COVID-19 guidance: personal protective equipment (PPE) for health care workers and health care entities version 1.0 [06-10-2022]

Canadian provinces and territories (other than Ontario)

WHO

• <u>Infection prevention and control in the context of coronavirus disease (COVID-19): a living guideline, 13 January 2023</u> [01-13-2023]

ECDC

 Considerations for infection prevention and control practices in relation to respiratory viral infections in healthcare settings [02-06-2023]

Back to Top

Appendix II: Guidelines for Health Sectors [ARCHIVED]

Healthcare Providers

Ontario Ministry of Health

- Management of cases and and contacts of COVID-19 in Ontario version 15.2 [03-27-2023]
- COVID-19 guidance: acute care v.9 [01-11-2023]

• COVID-19 guidance: personal protective equipment (PPE) for health care workers and health care entities version 1.0 [06-10-2022]

UK

• COVID-19: managing healthcare staff with symptoms of a respiratory infection [03-31-2023]

ECDC

- Considerations for infection prevention and control practices in relation to respiratory viral infections in healthcare settings [02-06-2023]
- <u>Living safely with respiratory infections, including COVID-19: when to consider wearing a face covering or a face mask</u> [06-16-2022]

Back to Top

Congregate Living (including Long-Term Care, Prisons, and Shelters)

Ontario Ministry of Health

- COVID-19 guidance document for long-term care homes in Ontario [04-03-2023]
- COVID-19 guidance: long-term care homes and retirement homes for public health units Version 10 [03-31-2023]

PHAC

 Infection prevention and control for COVID-19: interim guidance for long term care homes [01-25-2022]

CDC

- Guidance on prevention and management of COVID-19 in correctional and detention facilities [11-29-2022]
- Guidance on management of COVID-19 in homeless service sites and in correctional and detention facilities [11-29-2022]

UK

- Acute respiratory illness, including flu and COVID-19 in prisons [04-06-2023]
- Infection prevention and contgrol in adult social care: COVID-19 supplement [04-06-2023]
- COVID-19: outbreaks in prisons, refuges and other higher-risk accommodation settings [04-04-2023]

Other

CSC Testing of inmates in federal correctional institutions for COVID-19 [04-12-2023]

Back to Top

Appendix III: Guidelines for the Community [ARCHIVED]

Travel, Transport & Borders

Ontario Ministry of Health

• Travelling during COVID-19 [01-27-2023]

Canada

- Travel advide and advisories by destination [updated often]
- COVID-19: travel, testing and borders [04-03-2023]

CDC

- COVID-19 travel recommendations by destination [updated regularly]
- Stay up to date with your COVID-19 vaccines including Boosters [04-06-2023]

UK

COVID-19: guidance for people whose immune system means they are at higher risk [03-14-2023]

Schools / Childcare

Ontario Ministry of Health

- Management of cases and contacts of COVID-19 in Ontario version 15.2 [03-27-2023]
- COVID-19: health and safety measures for child care [08-17-2022]
- <u>COVID-19: health and safety measures at schools</u> [08-15-2022]

PHAC

• Evaluating COVID-19 disease transmission and public health measures in schools: outbreak investigation guidance [07-22-2022]

CDC

- Operational Guidance for K-12 Schools and Early Care and Education Programs to Support Safe
 In-Person Learning [10-05-2022]
- Schools, child care, and colleges [10-25-2022]

UK

• Emergency planning and response for education, childcare, and children's social care settings [10-28-2022]

Back to Top

Mental Health/Substance Use Health

Ontario Ministry of Health

• COVID-19 guidance: mental health and addictions service providers in community settings: version 2 [09-24-2020]

PHAC

• Helping people who use substances [10-01-2022]

Provinces & Territories (excluding Ontario)

- QC The roles of public health in population mental health and wellness promotion [10-03-2022]
- BC COVID-19: harm reduction and overdose response [01-07-2022]
- QC <u>Housing and social inequalities in health in times of COVID-19: strategies for promoting</u> affordable quality housing [04-05-2022]
- QC <u>Preventing violence and suicide within the context of the COVID-19 pandemic: courses of action</u> [04-05-2022]
- QC Preventing loneliness in young adults in the context of a pandemic [04-05-2022]
- BC Impacts of the COVID-19 pandemic on the health and wellbeing of young adults in British Columbia [07-00-2021]
- QC <u>Public health ethics and COVID-19</u>: selected resources [11-00-2021]

WHO

 Mental health and COVID-19: early evidence of the pandemic's impact: scientific brief, 2 March 2022 [03-02-2022]

Back to Top

Community/Workplaces

Ontario Ministry of Health

- Protection from COVID-19 and other respiratory illnesses [04-12-2023]
- COVID-19 and workplace health and safety [03-09-2023]
- COVID-19 and your employment standards protections [06-26-2022]
- Outbreak guidance: workplace and living settings for seasonal international agriculture workers (IAWs) [09-08-2022]

PHAC

- Summary of evidence supporting COVID-19 public health measures [01-27-2023]
- Community based public health measures [01-27-2023]
- How businesses and employees can stay safe while operating during COVID-19 [01-27-2023]
- Accessing public health support for First Nations communities [08-05-2022]
- COVID-19 and people with disabilities in Canada [01-30-2023]
- <u>COVID-19 mask use: advice for community settings</u> [01-30-2023]

WHO

• The generic all-hazards risk assessment and planning tool for mass gathering events [01-12-2023]

CDC

Specific settings [12-07-2022]

UK

- Infection prevention and control in adult social care: COVID-19 supplement [04-04-2023]
- Living safely with respiratory infections, including COVID-19 [06-16-2022]

Other

CCOHS daycares [07-14-2022]

Back to Top